Redburn Atlantic initiated coverage of Vertex Pharmaceuticals with a Buy rating and $545 price target. Vertex is among the “cleanest growth stories” in global biopharma, capable of delivering low double-digit sales and mid-teens earnings growth over the next five years and “top-tier revenue visibility into the next decade,” the analyst tells investors in a research note. The firm’s physician survey work supports our above-consensus outlooks for the company’s pipeline assets including suzetrigine in pain, Casgevy in sickle cell disease and VX880 in Type 1 diabetes.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- QQQ ETF Update, 6/26/2024
- Jefferies software analyst to hold analyst/industry conference call
- Vertex Pharmaceuticals price target raised to $555 from $540 at Wells Fargo
- Vertex reports ‘positive’ results from ongoing Phase 1/2 study of VX-880
- JPMorgan biotech analysts hold an analyst/industry conference call
Questions or Comments about the article? Write to editor@tipranks.com